<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypokalemic periodic paralysis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypokalemic periodic paralysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypokalemic periodic paralysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laurie Gutmann, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robin Conwit, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Periodic paralysis (PP) is a rare neuromuscular disorder related to a defect in muscle ion channels, characterized by episodes of painless muscle weakness, which may be precipitated by heavy exercise, fasting, or high-carbohydrate meals.</p><p>PP is classified as hypokalemic when episodes occur in association with low potassium blood levels or as hyperkalemic when episodes can be induced by elevated potassium. Most cases of PP are hereditary, usually with an autosomal dominant inheritance pattern. Acquired cases of hypokalemic PP have been described in association with hyperthyroidism. The clinical features of these disorders are summarized in the table  (<a class="graphic graphic_table graphicRef65215" href="/z/d/graphic/65215.html" rel="external">table 1</a>).</p><p>Hypokalemic PP and the PP associated with the Andersen syndrome will be reviewed here. Other causes of PP are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5152.html" rel="external">"Hyperkalemic periodic paralysis"</a> and  <a class="medical medical_review" href="/z/d/html/5154.html" rel="external">"Thyrotoxic periodic paralysis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Hypokalemic PP is the most common of the periodic paralyses, but is still quite rare, with an estimated prevalence of 1 in 100,000 [<a href="#rid1">1</a>]. Hypokalemic PP may be familial with autosomal dominant inheritance or may be acquired in patients with thyrotoxicosis [<a href="#rid2">2-7</a>]. (See  <a class="medical medical_review" href="/z/d/html/5154.html" rel="external">"Thyrotoxic periodic paralysis"</a>.)</p><p>Clinical penetrance is often incomplete, especially in females [<a href="#rid8">8,9</a>]. The disorder is three to four times more commonly clinically expressed in males. Approximately one-third of cases represent new mutations [<a href="#rid10">10,11</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Different genetic mutations have been found to underlie hypokalemic PP:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium channel disorders</strong> – A mutation in the gene that codes for the alpha-1 subunit of the dihydropyridine-sensitive calcium channel in skeletal muscle is the most common genetic abnormality in hypokalemic PP and is found in approximately 70 percent of patients [<a href="#rid12">12-15</a>].</p><p></p><p class="bulletIndent1">It is not known how the calcium channel defect leads to episodic potassium movement into the cells and causes weakness. Electrophysiologic studies have found a decreased calcium current density as well as slower rate of activation [<a href="#rid11">11,16,17</a>]. However, calcium movement is not clearly responsible for either altered potassium fluxes or clinical symptoms. In addition to calcium conductance, the dihydropyridine-sensitive calcium channel has been shown to also act as a voltage sensor for excitation-contraction coupling in skeletal muscle [<a href="#rid18">18</a>]. Investigators have found that hypokalemic PP is associated with a reduced sarcolemmal adenosine triphosphate (ATP)-sensitive potassium current [<a href="#rid19">19</a>]. This finding can be tied to the clinical manifestations of hypokalemic PP, but the relationship with the primary calcium channel defect is unclear. The investigators suggest the possibility of a secondary, calcium-sensitive channelopathy. In vitro studies showed that blocking the dihydropyridine-sensitive calcium channel in muscle fibers from patients with hypokalemic PP does not prevent insulin-induced membrane depolarization [<a href="#rid20">20</a>]. This is also consistent with a secondary channelopathy [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sodium channel disorders</strong> – A mutation in the skeletal muscle sodium channel, <em>SCN4A</em>, is responsible for this syndrome in other families [<a href="#rid21">21,22</a>]. Families with this mutation demonstrate more complete clinical penetrance, affecting males and females equally [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">The mechanism of paralysis in patients with sodium channel defect is better understood. Mutant sodium channels produce an anomalous gating pore current that may cause aberrant depolarization during attacks of weakness [<a href="#rid23">23-25</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – Kindreds with hypokalemic PP who have neither of these defects [<a href="#rid10">10,11</a>] and some with other potentially associated mutations [<a href="#rid26">26</a>] have been reported.</p><p></p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H4253671821"><span class="h2">Attacks</span><span class="headingEndMark"> — </span>As with all the periodic paralyses, attacks occur suddenly with generalized weakness. Consciousness is preserved and bulbar and respiratory muscles are only mildly affected, if at all.</p><p>In hypokalemic PP, attacks begin in late childhood or teenage years. These attacks vary in frequency and duration. Intervals of weeks to months are common, but some patients experience several attacks per week. Attacks typically last several hours, but the duration can range from minutes to days. Attacks may be triggered by rest after vigorous exercise, stress, or a high-carbohydrate meal, often after a delay of several hours. These events are often associated with an increased release of epinephrine or insulin, both of which cause movement of potassium into cells and low potassium blood levels [<a href="#rid2">2</a>]. One patient with known hypokalemic PP developed acute weakness after using an <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> inhaler [<a href="#rid27">27</a>].</p><p>Neurologic examination during an attack demonstrates weakness, usually affecting proximal more than distal muscles, and the legs more than the arms; hyporeflexia or areflexia is typical. Between attacks, the neurologic examination is usually normal; the myotonia typical of hyperkalemic PP is not a feature of hypokalemic PP. Some patients experience a milder degree of weakness between attacks that fluctuates and improves with mild exercise. Electromyography (EMG) findings during attacks are described below. (See <a class="local">'Electromyography'</a> below.)</p><p>The mean plasma potassium concentration during the attack in one series was 2.4 mEq/L [<a href="#rid10">10</a>]. Levels can be as low as 1.5; however, concentrations less than 2 mEq/L should suggest a secondary cause of hypokalemic paralysis, such as that seen in some cases of severe hypokalemia due to distal renal tubular acidosis (RTA). Between attacks, potassium levels normalize in hypokalemic PP, but remain low in secondary hypokalemia. (See  <a class="medical medical_review" href="/z/d/html/2327.html" rel="external">"Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance"</a>.)</p><p>Cardiac arrhythmias, such as tachycardia, atrial fibrillation, paroxysmal supraventricular tachycardia, or ventricular fibrillation, are not common but have been reported during attacks [<a href="#rid3">3</a>]. During attacks, the electrocardiogram (ECG) may otherwise show findings consistent with hypokalemia, including depression of the ST segment, decrease in the amplitude of the T wave, and an increase in the amplitude of U waves.  (<a class="graphic graphic_waveform graphicRef73888" href="/z/d/graphic/73888.html" rel="external">waveform 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2120.html" rel="external">"ECG tutorial: Miscellaneous diagnoses", section on 'Hypokalemia'</a>.)</p><p class="headingAnchor" id="H2844113943"><span class="h2">Myopathy</span><span class="headingEndMark"> — </span>A progressive proximal myopathy ultimately develops in most patients with hypokalemic PP [<a href="#rid28">28</a>]. This becomes clinically manifest in most individuals after the age of 50 years, as attacks of paralysis wane. Evidence of muscle disease may be evident on muscle biopsy, computed tomography scans, or magnetic resonance imaging several years before it manifests clinically [<a href="#rid28">28-30</a>]. In one study of 25 subjects, vacuoles containing glycogen were a consistent finding on muscle biopsy [<a href="#rid31">31</a>]. Clinically and pathologically, the myopathy is most profound in muscles of the pelvic girdle as well as the proximal upper and lower extremities. The severity of the myopathy is variable; patients may be only mildly affected or severely disabled. While a correlation between the severity of the myopathy and the number of paralytic attacks is suggested by some, there is little evidence to support this, and in at least one family, this association was not found [<a href="#rid28">28,32-34</a>]. </p><p class="headingAnchor" id="H3155475982"><span class="h2">Genetic-phenotypic associations</span><span class="headingEndMark"> — </span>Some suggest that hypokalemic PP associated with sodium channel abnormalities is phenotypically as well as genetically distinct from the calcium channel disorder, with more prominent myalgias, a younger age of onset, shorter duration of attacks, and less severe myopathy [<a href="#rid10">10,21</a>]. Worsening, rather than improvement of symptoms with <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a>, occurs in some, but not all, patients with the sodium channel variant of hypokalemic PP. (See <a class="local">'Preventive treatment'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Hypokalemic PP must be distinguished from other causes of PP, which are discussed separately. In particular, paralytic attacks in thyrotoxicosis and in the Andersen syndrome can be associated with hypokalemia and must be explicitly excluded because treatment and preventive strategies are different in these disorders. The distinguishing clinical features of these disorders are summarized in the table  (<a class="graphic graphic_table graphicRef65215" href="/z/d/graphic/65215.html" rel="external">table 1</a>). (See <a class="local">'Andersen syndrome'</a> below and  <a class="medical medical_review" href="/z/d/html/5152.html" rel="external">"Hyperkalemic periodic paralysis"</a> and  <a class="medical medical_review" href="/z/d/html/4836.html" rel="external">"Neurologic manifestations of hyperthyroidism and Graves' disease", section on 'Thyrotoxic periodic paralysis'</a>.)</p><p>Other disorders that can cause intermittent muscle weakness include:</p><p class="bulletIndent1"><span class="glyph">●</span>Myasthenia gravis. Weakness in myasthenia gravis typically occurs predictably in the setting of milder degrees of exertion, does not occur in "attacks" as does PP, and often involves bulbar and extraocular muscles, which are rarely if ever affected in hypokalemic PP. In contrast to PP, when profound weakness occurs in a myasthenic crisis, respiratory muscle involvement is common. (See  <a class="medical medical_review" href="/z/d/html/5170.html" rel="external">"Clinical manifestations of myasthenia gravis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic myopathies. Patients with a metabolic myopathy typically complain of exercise intolerance, with myalgias and muscle fatigability, rather than attacks of weakness. Myoglobinuria may accompany or follow more severe symptoms. (See  <a class="medical medical_review" href="/z/d/html/6193.html" rel="external">"Approach to the metabolic myopathies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary hypokalemia. Episodic weakness may be seen in association with severe hypokalemia due to renal, gastrointestinal, or other causes including Sjögren's disease [<a href="#rid35">35-42</a>]. There is typically clinical or laboratory evidence of the underlying systemic disease, and hypokalemia persists between attacks. (See  <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2341.html" rel="external">"Causes of hypokalemia in adults"</a>.)</p><p></p><p>In a first attack of quadriparesis, other diagnoses such as Guillain-Barré syndrome, acute myelopathy (eg, transverse myelitis), myasthenic crisis, tick paralysis, and botulism may be considered initially. However, the finding of hypokalemia generally alerts the clinician to the diagnosis of hypokalemic PP.</p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>When there is an established family history of hypokalemic PP, episodes of PP often require no further diagnostic evaluation. Otherwise, the diagnosis of hypokalemic PP is suggested by documentation of hypokalemia during a typical attack of weakness. Even when this is demonstrated, other testing is required to rule out alternative diagnoses.</p><p>When patients are evaluated after or between attacks, the diagnosis may be difficult. Further diagnostic options include genetic tests, provocative testing, and electromyography (EMG). No diagnostic criteria are published for this disorder; a diagnosis is based upon the preponderance of findings consistent with the disorder along with response to treatment.</p><p class="headingAnchor" id="H7"><span class="h2">Initial laboratory evaluation</span><span class="headingEndMark"> — </span>During an acute attack, measurement of serum potassium is required, both for diagnosis and to guide treatment. (See <a class="local">'Acute treatment'</a> below.)</p><p>Other testing is also required to rule out alternative diagnoses:</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthyroidism should be excluded with laboratory testing: T3, T4, and thyroid-stimulating hormone (TSH) levels. In the acute setting, findings of tachycardia and hypophosphatemia can raise suspicion of this disorder [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/4836.html" rel="external">"Neurologic manifestations of hyperthyroidism and Graves' disease", section on 'Thyrotoxic periodic paralysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An ECG should be performed to identify a prolonged QT or QU interval suggestive of Andersen syndrome  (<a class="graphic graphic_waveform graphicRef77018" href="/z/d/graphic/77018.html" rel="external">waveform 2</a>) (see <a class="local">'Andersen syndrome'</a> below). During an attack of hypokalemic PP, the ECG may otherwise show findings consistent with hypokalemia, including depression of the ST segment, decrease in the amplitude of the T wave, and an increase in the amplitude of U waves.  (<a class="graphic graphic_waveform graphicRef73888" href="/z/d/graphic/73888.html" rel="external">waveform 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2120.html" rel="external">"ECG tutorial: Miscellaneous diagnoses", section on 'Hypokalemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An arterial blood gas, blood urea nitrogen, creatinine, and other electrolytes (phosphate, calcium, and magnesium) should be measured during an acute attack. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one case series, a metabolic acidosis or alkalosis was found in all cases with secondary hypokalemia and in none of the patients with PP [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypophosphatemia can cause acute paralysis in patients with diabetic ketoacidosis who may also have hypokalemia [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one study, the following findings during an acute attack were reliable tests to distinguish hypokalemic PP from secondary hypokalemic paralysis: a low urine potassium-creatinine concentration ratio (&lt;22 mEq/g or &lt;2.5 mEq/mmol) and a low transtubular potassium concentration gradient (&lt;3.0) as calculated from (urine K/plasma K) ÷ (urine osmolality/plasma osmolality) [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/2305.html" rel="external">"Evaluation of the adult patient with hypokalemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal plasma potassium levels between attacks help distinguish primary hypokalemic PP from other secondary causes of hypokalemic paralysis, such as distal renal tubular acidosis (RTA) [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/2327.html" rel="external">"Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance"</a>.)</p><p></p><p>The value of these tests is illustrated in case series. Diagnostic evaluation in 34 patients with episodic weakness from Thailand determined that 11 had thyrotoxic PP, 8 had distal RTA, and 15 had hypokalemic PP [<a href="#rid46">46</a>]. Hypokalemic PP occurred without a known family history in two-thirds of cases. Among those with RTA, a metabolic acidosis was noted in only two patients. Only subtle clinical signs of hyperthyroidism were observed in 4 of 11 patients with hyperthyroidism. In a larger case series of 97 patients with an initial diagnosis of hypokalemic PP in the emergency department, 31 had hypokalemic PP, 39 had thyrotoxic PP, and 24 had secondary hypokalemia (RTA, aldosteronism, Bartter syndrome, others) [<a href="#rid43">43</a>]. Only two patients with hypokalemic PP had a family history in this series.</p><p class="headingAnchor" id="H8"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>It is possible to test for many but not all of the mutations that underlie hypokalemic PP. (See <a class="local">'Pathogenesis'</a> above.)</p><p>When an associated mutation is found, this is sufficient to make a positive diagnosis in a patient with typical clinical symptoms. </p><p>When genetic testing is negative, further testing with provocative testing and/or EMG may help establish the diagnosis of hypokalemic PP.</p><p class="headingAnchor" id="H9"><span class="h2">Provocative testing</span><span class="headingEndMark"> — </span>Provocative testing can be employed when genetic testing fails to identify an underlying mutation. Careful monitoring, usually in an inpatient setting, is recommended for all forms of provocative testing:</p><p class="bulletIndent1"><span class="glyph">●</span>Precipitating an attack of hypokalemic PP with an oral glucose load, 2 g/kg, and/or insulin administration, 10 units subcutaneously, is an option, but this can be risky [<a href="#rid47">47</a>]. This should be done in an inpatient setting with continuous cardiac monitoring and with availability of emergency resuscitative measures in case cardiac arrhythmias occur. Preexisting cardiac or renal disease precludes such testing and should be excluded prior to this test.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exercise, such as 30 minutes of running on the treadmill, may provide a safer alternative to glucose or insulin administration. A positive response, weakness with accompanying hypokalemia, is more helpful than a negative response, because some patients do not have reliably induced attacks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both hypokalemic PP and hyperkalemic PP can be induced with corticotropin (ACTH). In one study, in five patients with suspected hypokalemic PP, ACTH 80 to 100 international units intramuscular was administered in the evening [<a href="#rid48">48</a>]. Muscle strength was assessed in the hand with a dynamometer at baseline and every one to two hours, along with measurement of serum potassium. Weakness was observed along with a fall in serum potassium to &lt;2.5 mmol/L 13 to 27 hours after ACTH administration in four patients. Significant side effects did not occur, but hospitalization and careful monitoring is recommended for provocative testing.</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Electromyography</span><span class="headingEndMark"> — </span>During an attack, EMG may show decreased amplitude of the compound muscle action potential (CMAP), with reduced motor unit recruitment or electrical silence, depending on the severity of weakness [<a href="#rid11">11,47,49</a>]. Other findings more variably described include increased insertional activity, increased polyphasic motor unit potentials, and reduced muscle fiber conduction velocity.</p><p>The presence of myotonia on EMG strongly suggests the alternative diagnosis of hyperkalemic PP. This finding is seen in up to 80 percent of patients with hyperkalemic PP, in no patients with hypokalemic PP associated with the calcium channel defect, and rarely in patients with the sodium channel variant of hypokalemic PP or without an identified mutation [<a href="#rid10">10,50</a>]. (See  <a class="medical medical_review" href="/z/d/html/5152.html" rel="external">"Hyperkalemic periodic paralysis"</a>.)</p><p>When myasthenia gravis is considered, other techniques such as repetitive nerve stimulation and single-fiber EMG are useful tests. (See  <a class="medical medical_review" href="/z/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis"</a>.)</p><p class="headingAnchor" id="H1480497432"><span class="h3">Exercise test</span><span class="headingEndMark"> — </span>An EMG technique that may be used to help confirm the diagnosis between attacks is the "long exercise test" (LET), which is more likely to be abnormal than the short exercise test in this disorder [<a href="#rid51">51,52</a>]. CMAPs following a single supramaximal electrical stimulus are recorded at rest and every one to two minutes following two to five minutes of exercise [<a href="#rid53">53</a>]. Exercise consists of maximal contraction of a muscle (biceps or anterior tibialis) for two to five minutes with three- to four-second rest periods every 15 seconds. A gradual reduction of over 40 percent in the evoked motor amplitude after 30 to 40 minutes is compatible with a diagnosis of PP but is not specific to hypokalemic PP [<a href="#rid51">51,53</a>]. </p><p>This test had a sensitivity of 71 percent in a case series of patients with PP (either hypokalemic PP, hyperkalemic PP, or thyrotoxic PP) [<a href="#rid53">53</a>]. The sensitivity declines when attacks have not been recent [<a href="#rid54">54</a>]. In one case series, 67 patients with episodic paralysis and suspected PP had both LET and genetic testing [<a href="#rid52">52</a>]. The overall sensitivity of LET for genetically confirmed PP was 71 percent; those with more frequent attacks of paralysis were more likely to have positive LET. Thus, a negative LET in the setting of frequent attacks makes a diagnosis very unlikely; however, a negative LET does not rule out PP in less severely affected patients. Electrophysiologic short exercise testing before LET resulted in a false-negative test for some patients who had both tests at the same session. Other investigators have found that the test is also highly specific (97 to 98 percent) for muscle ion channel disorders [<a href="#rid54">54,55</a>].</p><p>One report suggests that the LET can discriminate between types of PP. These investigators found that an initial increase in CMAP followed by a delayed decrease was seen in five of six patients with hyperkalemic PP after short-duration exercise (10 to 12 seconds) and in only 1 of 13 patients with hypokalemic PP associated with a calcium channel defect [<a href="#rid56">56</a>]. Of the two patients with the sodium channel variant of hypokalemic PP, one had this finding. </p><p class="headingAnchor" id="H11"><span class="h2">Muscle biopsy</span><span class="headingEndMark"> — </span>A muscle biopsy is not usually performed in the diagnosis of PP. Vacuolar changes, representing reduplication of the sarcoplasmic reticulum and transverse tubules, are invariably found but are nonspecific findings common to all periodic paralyses [<a href="#rid11">11,31</a>]. Tubular aggregates are less often seen, but may be more common in the sodium channel mutation variant of hypokalemic PP and in the Andersen syndrome [<a href="#rid11">11</a>]. </p><p>More significant myopathic changes on muscle biopsy are described in patients who develop the progressive myopathy, usually several years after their initial presentation [<a href="#rid28">28,29</a>]. However, in one cross-sectional study of patients with hypokalemic PP and calcium voltage-gated channel subunit alpha1 S (<em>CACNA1S</em>) mutations, vacuolar change appeared independently of the frequency or severity of attacks or the patient's age [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H12"><span class="h1">ACUTE TREATMENT</span><span class="headingEndMark"> — </span>The oral administration of 60 to 120 mEq of <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a>, given incrementally, usually aborts acute attacks of hypokalemic PP. Recovery may take minutes to hours. Important caveats of acute treatment include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of hypokalemia must be confirmed prior to therapy, since potassium administration can worsen episodes due to hyperkalemic PP [<a href="#rid2">2,57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potassium administration during an acute episode may lead to posttreatment hyperkalemia as potassium moves back out of the cells [<a href="#rid3">3,5,40,58-60</a>]. Treatment should therefore be administered incrementally, and posttreatment potassium levels should be monitored for 24 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potassium should not be administered in solutions containing dextrose, as patients have an exaggerated insulin response to carbohydrate loads [<a href="#rid61">61,62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac monitoring is recommended during treatment and posttreatment monitoring.</p><p></p><p>A suggested protocol is <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a> 30 mEq orally every 30 minutes until serum potassium normalizes [<a href="#rid11">11</a>]. However, some recommend slower rates of administration, 10 mEq per hour, to minimize rebound hyperkalemia [<a href="#rid40">40</a>].</p><p>Milder attacks can be aborted by low-level exercise [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H13"><span class="h1">PREVENTIVE TREATMENT</span><span class="headingEndMark"> — </span>Nonpharmacologic interventions that may be effective for preventing attacks include a low-carbohydrate diet and refraining from vigorous exercise. When attacks continue to be disabling, prophylactic treatment is indicated to avoid morbidity, even mortality, which can be associated with hospitalization and acute treatment [<a href="#rid63">63</a>]. Medications, symptomatic potassium supplementation, potassium-sparing diuretics, and carbonic anhydrase inhibitors are used when lifestyle changes are not sufficiently effective [<a href="#rid3">3,64,65</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Carbonic anhydrase inhibitors appear to be effective in reducing attacks of PP. <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">Acetazolamide</a> 250 mg twice daily is commonly reported to be effective in reducing attacks [<a href="#rid1">1,11,66</a>]. The subset of patients who experience mild, fluctuating weakness between attacks reportedly find acetazolamide treatment helpful [<a href="#rid1">1</a>]. However, one retrospective study found that only half of patients respond to acetazolamide therapy [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="103310" href="/z/d/drug information/103310.html" rel="external">Dichlorphenamide</a> 50 mg twice daily was demonstrated to be more effective than placebo in reducing attack frequency in the only clinical trial demonstrating a benefit for treatment in PP [<a href="#rid68">68,69</a>]. Previously unavailable in the United States, dichlorphenamide was approved for treatment of hypokalemic PP by the US Food and Drug Administration (FDA) in August 2015 [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1">In one case report, two twin boys with attacks refractory to a combined <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a> and <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> regimen were treated with <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> 75 to 100 mg twice daily [<a href="#rid71">71</a>]. While attack frequency increased, the severity of individual attacks was decreased, resulting in fewer emergency department visits and an overall improved quality of life.</p><p></p><p class="bulletIndent1">The mechanism whereby carbonic anhydrase inhibitors are effective in hypokalemic PP is not clear, but appears to be independent of carbonic anhydrase inhibition [<a href="#rid72">72,73</a>]. Studies in animal models suggest that these agents trigger calcium-activated potassium channels on skeletal muscle. Side effects such as malaise and fatigue limit tolerability in some patients [<a href="#rid68">68</a>]. Kidney stones are a potential complication of treatment with these agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A potassium-sparing diuretic, either <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> 100 mg daily or <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">triamterene</a> 150 mg daily, can be effective as monotherapy or as a supplement to carbonic anhydrase inhibitor [<a href="#rid11">11</a>]. Potassium supplementation should be avoided in these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The efficacy of <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> 240 mg daily was studied for three weeks in nine patients using a randomized, crossover design [<a href="#rid66">66</a>]. While verapamil treatment was not associated with a reduced frequency of events in the group as a whole, two patients experienced significant reduction of events on verapamil.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pinacidil, a potassium channel opener, (not available in the United States) appeared to improve strength during episodes of induced hyperglycemia compared with placebo in four patients with hypokalemic PP [<a href="#rid69">69,74</a>]. However, no clinical paralytic attacks were provoked in either the placebo- or pinacidil-treated patients in this study.</p><p></p><p>The efficacy of these interventions may vary with the specific mutation, but this requires further analysis. In one retrospective review of 74 patients, those with mutations in <em>CACNA1S</em> were more likely to respond to treatment with <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a> compared with those with <em>SCN4A</em> mutation (56 versus 16 percent) [<a href="#rid67">67</a>]. In other reports, some family members with a specific mutation in the calcium channel had marked improvement with treatment with potassium-sparing diuretics after failing to respond to acetazolamide [<a href="#rid75">75,76</a>]. Acetazolamide has been reported to exacerbate symptoms in some families with mutations in the sodium channel, but not in others [<a href="#rid21">21,77</a>].</p><p>There is no known treatment for the late-onset myopathy in hypokalemic PP. While some believe that limiting attacks of PP ameliorates the subsequent myopathy, this is unproven [<a href="#rid28">28,32,33</a>].</p><p>The association between malignant hyperthermia and hypokalemia is uncertain, but has been described [<a href="#rid63">63</a>], suggesting caution be used when certain inhalational anesthetic agents or <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> are used. (See  <a class="medical medical_review" href="/z/d/html/403.html" rel="external">"Susceptibility to malignant hyperthermia: Evaluation and management"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">ANDERSEN SYNDROME</span><span class="headingEndMark"> — </span>A rare disorder, estimated at one-tenth the prevalence of hypokalemic PP, the Andersen-Tawil or Andersen syndrome is clinically and genetically distinct from other periodic paralyses. It is manifested by a triad of PP, ventricular dysrhythmias, and dysmorphic features (short stature, hypertelorism, clinodactyly, micrognathia) [<a href="#rid78">78-81</a>]. A prolonged QT interval on ECG is also a feature of this disorder  (<a class="graphic graphic_waveform graphicRef77018" href="/z/d/graphic/77018.html" rel="external">waveform 2</a>). (See  <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">"Congenital long QT syndrome: Epidemiology and clinical manifestations", section on 'Andersen-Tawil syndrome'</a>.)</p><p>Potassium may be low, normal, or high during paralytic attacks, which first manifest during the first or second decade of life [<a href="#rid11">11,78-80,82</a>]. Low potassium levels are noted somewhat more frequently. Similar to other syndromes, paralytic attacks are commonly precipitated by rest after exercise. However, a dietary trigger is rarely identified. Provocative challenges to induce hypokalemia or hyperkalemia should not be performed in these patients because of the risk of cardiac arrhythmias.</p><p>A mutation in the gene encoding Kir2.1, an inward rectifier potassium channel expressed in cardiac and skeletal muscle, is identified in approximately two-thirds of patients. Nonpenetrance occurs in approximately 20 percent of individuals who inherit the mutation. Incomplete penetrance and marked intrafamilial phenotypic variation is also common; isolated features, particularly a long QT interval, may be manifest in family members who exhibit no other features of the disease [<a href="#rid79">79,83</a>]. The function of Kir2.1 is better established in cardiac than skeletal muscle; however, a reduction in inward potassium movement is thought to lead to sodium channel inactivation and persistent membrane depolarization. A second gene encoding the G-protein-activated inwardly rectifying potassium channel Kir3.4 has also been shown to cause the Andersen syndrome [<a href="#rid84">84</a>].</p><p>There is little information on the treatment or prognosis of PP in this setting. Myopathic weakness is described in some cases of Andersen syndrome, and myopathic changes and tubular aggregates are described on muscle biopsy [<a href="#rid82">82,83</a>]. Treatment is complicated by the potential to precipitate cardiac arrhythmias; diuretics are contraindicated in patients with the long QT syndrome. Carbonic anhydrase inhibitors, <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a> and <a class="drug drug_general" data-topicid="103310" href="/z/d/drug information/103310.html" rel="external">dichlorphenamide</a>, are reportedly useful in controlling attacks of weakness in some patients [<a href="#rid11">11,78,82,83</a>].</p><p class="headingAnchor" id="H12414131"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83672.html" rel="external">"Patient education: Periodic paralysis syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Hypokalemic periodic paralysis (PP) is a rare inherited neuromuscular disorder, manifested by episodes of painless muscle weakness that may be triggered by rest after vigorous exercise, stress, or a high-carbohydrate meal. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1">The distinguishing clinical features of hypokalemic PP in contrast to other PP disorders (thyrotoxic PP, hyperkalemic PP, and the Andersen syndrome) are summarized in the table  (<a class="graphic graphic_table graphicRef65215" href="/z/d/graphic/65215.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – In an acute attack, the diagnosis of familial hypokalemic PP is made by documentation of hypokalemia and excluding thyrotoxicosis and secondary causes of hypokalemia. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1">An ECG should also be performed in all patients with PP to exclude a long QT or QU interval suggesting Andersen syndrome. (See <a class="local">'Diagnostic evaluation'</a> above and <a class="local">'Andersen syndrome'</a> above.)</p><p></p><p class="bulletIndent1">Genetic testing is available for most, but not all, of the mutations underlying hypokalemic PP. Genetic testing may be unnecessary if there is an established family history. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1">When genetic testing is negative, electromyography (EMG) can be useful in the interictal evaluation of patients with PP, distinguishing hypokalemic PP from other periodic paralyses and other causes of intermittent weakness. (See <a class="local">'Electromyography'</a> above.)</p><p></p><p class="bulletIndent1">We recommend not performing provocative testing with glucose loading or insulin administration as a routine test for hypokalemic PP. Monitoring weakness and potassium levels before and after exercise or corticotropin (ACTH) administration is a safer alternative. (See <a class="local">'Provocative testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of acute attacks</strong> – In an acute disabling attack, we recommend administering oral potassium (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Patients should be on cardiac monitoring, hypokalemia should be verified prior to treatment, and potassium levels should be monitored for potential rebound hyperkalemia for 24 hours. A suggested treatment protocol is potassium 30 mEq every 30 minutes until hypokalemia and weakness resolve. (See <a class="local">'Acute treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventive strategies and prophylactic treatment</strong> – Nonpharmacologic preventive strategies in hypokalemic PP include avoiding strenuous exercise and high carbohydrate loads. (See <a class="local">'Preventive treatment'</a> above.)</p><p></p><p class="bulletIndent1">For patients who continue to have disabling attacks, we recommend prophylactic treatment with a carbonic anhydrase inhibitor, either <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a> 250 mg twice daily or <a class="drug drug_general" data-topicid="103310" href="/z/d/drug information/103310.html" rel="external">dichlorphenamide</a> 50 mg twice daily (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Because a minority of patients have more attacks with this treatment, close monitoring is recommended during initiation.</p><p></p><p class="bulletIndent1">We suggest potassium-sparing diuretics (eg, <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> 100 mg daily) as a supplement to the carbonic anhydrase inhibitor or as an alternative if a patient worsens on or cannot tolerate the carbonic anhydrase inhibitor (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Preventive treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Most patients with hypokalemic PP develop a myopathy in later life. The severity is variable. There are no known strategies to prevent or ameliorate the development of weakness. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Andersen syndrome</strong> – The Andersen syndrome is a rare inherited disorder, manifested by a triad of PP (which may be associated with low, normal, or high potassium levels), ventricular arrhythmias, and dysmorphic features. A long QT or long QU interval on ECG suggests this disorder in a patient with PP. Carbonic anhydrase inhibitors are reported to limit attacks of weakness in some patients. (See <a class="local">'Andersen syndrome'</a> above and  <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">"Congenital long QT syndrome: Epidemiology and clinical manifestations", section on 'Andersen-Tawil syndrome'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fontaine B. Periodic paralysis. Adv Genet 2008; 63:3.</a></li><li><a class="nounderline abstract_t">Fontaine B, Lapie P, Plassart E, et al. Periodic paralysis and voltage-gated ion channels. Kidney Int 1996; 49:9.</a></li><li><a class="nounderline abstract_t">Ober KP. Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature. Medicine (Baltimore) 1992; 71:109.</a></li><li><a class="nounderline abstract_t">Chan A, Shinde R, Chow CC, et al. In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. BMJ 1991; 303:1096.</a></li><li><a class="nounderline abstract_t">Ko GT, Chow CC, Yeung VT, et al. Thyrotoxic periodic paralysis in a Chinese population. QJM 1996; 89:463.</a></li><li><a class="nounderline abstract_t">Lin SH. Thyrotoxic periodic paralysis. Mayo Clin Proc 2005; 80:99.</a></li><li><a class="nounderline abstract_t">Kung AW. Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab 2006; 91:2490.</a></li><li><a class="nounderline abstract_t">Elbaz A, Vale-Santos J, Jurkat-Rott K, et al. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families. Am J Hum Genet 1995; 56:374.</a></li><li><a class="nounderline abstract_t">Ke Q, Luo B, Qi M, et al. Gender differences in penetrance and phenotype in hypokalemic periodic paralysis. Muscle Nerve 2013; 47:41.</a></li><li><a class="nounderline abstract_t">Miller TM, Dias da Silva MR, Miller HA, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology 2004; 63:1647.</a></li><li><a class="nounderline abstract_t">Venance SL, Cannon SC, Fialho D, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain 2006; 129:8.</a></li><li><a class="nounderline abstract_t">Ptácek LJ, Tawil R, Griggs RC, et al. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell 1994; 77:863.</a></li><li><a class="nounderline abstract_t">Sillén A, Sørensen T, Kantola I, et al. Identification of mutations in the CACNL1A3 gene in 13 families of Scandinavian origin having hypokalemic periodic paralysis and evidence of a founder effect in Danish families. Am J Med Genet 1997; 69:102.</a></li><li><a class="nounderline abstract_t">Wang Q, Liu M, Xu C, et al. Novel CACNA1S mutation causes autosomal dominant hypokalemic periodic paralysis in a Chinese family. J Mol Med (Berl) 2005; 83:203.</a></li><li><a class="nounderline abstract_t">Matthews E, Labrum R, Sweeney MG, et al. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology 2009; 72:1544.</a></li><li><a class="nounderline abstract_t">Lapie P, Goudet C, Nargeot J, et al. Electrophysiological properties of the hypokalaemic periodic paralysis mutation (R528H) of the skeletal muscle alpha 1s subunit as expressed in mouse L cells. FEBS Lett 1996; 382:244.</a></li><li><a class="nounderline abstract_t">Morrill JA, Brown RH Jr, Cannon SC. Gating of the L-type Ca channel in human skeletal myotubes: an activation defect caused by the hypokalemic periodic paralysis mutation R528H. J Neurosci 1998; 18:10320.</a></li><li><a class="nounderline abstract_t">Tanabe T, Beam KG, Powell JA, Numa S. Restoration of excitation-contraction coupling and slow calcium current in dysgenic muscle by dihydropyridine receptor complementary DNA. Nature 1988; 336:134.</a></li><li><a class="nounderline abstract_t">Tricarico D, Servidei S, Tonali P, et al. Impairment of skeletal muscle adenosine triphosphate-sensitive K+ channels in patients with hypokalemic periodic paralysis. J Clin Invest 1999; 103:675.</a></li><li><a class="nounderline abstract_t">Ruff RL. Insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K+ current. Neurology 1999; 53:1556.</a></li><li><a class="nounderline abstract_t">Sternberg D, Maisonobe T, Jurkat-Rott K, et al. Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain 2001; 124:1091.</a></li><li><a class="nounderline abstract_t">Bulman DE, Scoggan KA, van Oene MD, et al. A novel sodium channel mutation in a family with hypokalemic periodic paralysis. Neurology 1999; 53:1932.</a></li><li><a class="nounderline abstract_t">Francis DG, Rybalchenko V, Struyk A, Cannon SC. Leaky sodium channels from voltage sensor mutations in periodic paralysis, but not paramyotonia. Neurology 2011; 76:1635.</a></li><li><a class="nounderline abstract_t">Sokolov S, Scheuer T, Catterall WA. Gating pore current in an inherited ion channelopathy. Nature 2007; 446:76.</a></li><li><a class="nounderline abstract_t">Jiang D, Gamal El-Din TM, Ing C, et al. Structural basis for gating pore current in periodic paralysis. Nature 2018; 557:590.</a></li><li><a class="nounderline abstract_t">Groome JR, Lehmann-Horn F, Fan C, et al. NaV1.4 mutations cause hypokalaemic periodic paralysis by disrupting IIIS4 movement during recovery. Brain 2014; 137:998.</a></li><li><a class="nounderline abstract_t">Tucker C, Villanueva L. Acute hypokalemic periodic paralysis possibly precipitated by albuterol. Am J Health Syst Pharm 2013; 70:1588.</a></li><li><a class="nounderline abstract_t">Links TP, Zwarts MJ, Wilmink JT, et al. Permanent muscle weakness in familial hypokalaemic periodic paralysis. Clinical, radiological and pathological aspects. Brain 1990; 113 ( Pt 6):1873.</a></li><li><a class="nounderline abstract_t">Gold R, Reichmann H. Muscle pathology correlates with permanent weakness in hypokalemic periodic paralysis: a case report. Acta Neuropathol 1992; 84:202.</a></li><li><a class="nounderline abstract_t">Holm-Yildiz S, Witting N, Dahlqvist J, et al. Permanent muscle weakness in hypokalemic periodic paralysis. Neurology 2020; 95:e342.</a></li><li><a class="nounderline abstract_t">Holm-Yildiz S, Krag T, Witting N, et al. Vacuoles, Often Containing Glycogen, Are a Consistent Finding in Hypokalemic Periodic Paralysis. J Neuropathol Exp Neurol 2020; 79:1127.</a></li><li><a class="nounderline abstract_t">Griggs RC, Engel WK, Resnick JS. Acetazolamide treatment of hypokalemic periodic paralysis. Prevention of attacks and improvement of persistent weakness. Ann Intern Med 1970; 73:39.</a></li><li><a class="nounderline abstract_t">Dalakas MC, Engel WK. Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis. Muscle Nerve 1983; 6:182.</a></li><li><a class="nounderline abstract_t">Links TP, Smit AJ, Molenaar WM, et al. Familial hypokalemic periodic paralysis. Clinical, diagnostic and therapeutic aspects. J Neurol Sci 1994; 122:33.</a></li><li><a class="nounderline abstract_t">Cheng CJ, Chen YH, Chau T, Lin SH. A hidden cause of hypokalemic paralysis in a patient with prostate cancer. Support Care Cancer 2004; 12:810.</a></li><li><a class="nounderline abstract_t">Fujimoto T, Shiiki H, Takahi Y, Dohi K. Primary Sjögren's syndrome presenting as hypokalaemic periodic paralysis and respiratory arrest. Clin Rheumatol 2001; 20:365.</a></li><li><a class="nounderline abstract_t">Chang YC, Huang CC, Chiou YY, Yu CY. Renal tubular acidosis complicated with hypokalemic periodic paralysis. Pediatr Neurol 1995; 13:52.</a></li><li><a class="nounderline abstract_t">Agarwal AK, Wadhwa S, Wali M. Hypokalaemic periodic paralysis associated with thyrotoxicosis. J Assoc Physicians India 1994; 42:261.</a></li><li><a class="nounderline abstract_t">Ahlawat SK, Sachdev A. Hypokalaemic paralysis. Postgrad Med J 1999; 75:193.</a></li><li><a class="nounderline abstract_t">Lin SH, Lin YF, Chen DT, et al. Laboratory tests to determine the cause of hypokalemia and paralysis. Arch Intern Med 2004; 164:1561.</a></li><li><a class="nounderline abstract_t">Sung CC, Cheng CJ, Chiang WF, et al. Etiologic and therapeutic analysis in patients with hypokalemic nonperiodic paralysis. Am J Med 2015; 128:289.</a></li><li><a class="nounderline abstract_t">Paliwal VK, Rai AS, Kumar S, et al. Proximal Muscle Weakness With Overlying Hypokalemic Periodic Paralysis in Sjögren Syndrome: Report of 6 Cases. J Clin Rheumatol 2020; 26:24.</a></li><li><a class="nounderline abstract_t">Lin SH, Lin YF, Halperin ML. Hypokalaemia and paralysis. QJM 2001; 94:133.</a></li><li><a class="nounderline abstract_t">Liu PY, Jeng CY. Severe hypophosphatemia in a patient with diabetic ketoacidosis and acute respiratory failure. J Chin Med Assoc 2004; 67:355.</a></li><li><a class="nounderline abstract_t">Ng HY, Lin SH, Hsu CY, et al. Hypokalemic paralysis due to Gitelman syndrome: a family study. Neurology 2006; 67:1080.</a></li><li><a class="nounderline abstract_t">Phakdeekitcharoen B, Ruangraksa C, Radinahamed P. Hypokalaemia and paralysis in the Thai population. Nephrol Dial Transplant 2004; 19:2013.</a></li><li class="breakAll">Cannon SC, George AL. Pathophysiology of myotonia and periodic paralysis. In: Diseases of the Nervous System, 3rd ed, Asbury AK, McKhann GM, McDonald WI, et al (Eds), Cambridge University Press, Cambridge 2002. p.1183.</li><li><a class="nounderline abstract_t">Streeten DH, Speller PJ, Fellerman H. Use of corticotropin-induced potassium changes in the diagnosis of both hypo- and hyperkalemic periodic paralysis. Eur Neurol 1993; 33:103.</a></li><li><a class="nounderline abstract_t">Sharma CM, Nath K, Parekh J. Reversible electrophysiological abnormalities in hypokalemic paralysis: Case report of two cases. Ann Indian Acad Neurol 2014; 17:100.</a></li><li><a class="nounderline abstract_t">Sugiura Y, Makita N, Li L, et al. Cold induces shifts of voltage dependence in mutant SCN4A, causing hypokalemic periodic paralysis. Neurology 2003; 61:914.</a></li><li><a class="nounderline abstract_t">Simmons DB, Lanning J, Cleland JC, et al. Long Exercise Test in Periodic Paralysis: A Bayesian Analysis. Muscle Nerve 2019; 59:47.</a></li><li><a class="nounderline abstract_t">Ribeiro A, Suetterlin KJ, Skorupinska I, et al. The long exercise test as a functional marker of periodic paralysis. Muscle Nerve 2022; 65:581.</a></li><li><a class="nounderline abstract_t">McManis PG, Lambert EH, Daube JR. The exercise test in periodic paralysis. Muscle Nerve 1986; 9:704.</a></li><li><a class="nounderline abstract_t">Tengan CH, Antunes AC, Gabbai AA, Manzano GM. The exercise test as a monitor of disease status in hypokalaemic periodic paralysis. J Neurol Neurosurg Psychiatry 2004; 75:497.</a></li><li><a class="nounderline abstract_t">Kuntzer T, Flocard F, Vial C, et al. Exercise test in muscle channelopathies and other muscle disorders. Muscle Nerve 2000; 23:1089.</a></li><li><a class="nounderline abstract_t">Fournier E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol 2004; 56:650.</a></li><li class="breakAll">Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th, McGraw-Hill, New York 2001. p.836.</li><li><a class="nounderline abstract_t">Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Arch Intern Med 1999; 159:601.</a></li><li><a class="nounderline abstract_t">Tassone H, Moulin A, Henderson SO. The pitfalls of potassium replacement in thyrotoxic periodic paralysis: a case report and review of the literature. J Emerg Med 2004; 26:157.</a></li><li><a class="nounderline abstract_t">Lu KC, Hsu YJ, Chiu JS, et al. Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis. Am J Emerg Med 2004; 22:544.</a></li><li><a class="nounderline abstract_t">Loh KC, Pinheiro L, Ng KS. Thyrotoxic periodic paralysis complicated by near-fatal ventricular arrhythmias. Singapore Med J 2005; 46:88.</a></li><li><a class="nounderline abstract_t">Griggs RC, Resnick J, Engel WK. Intravenous treatment of hypokalemic periodic paralysis. Arch Neurol 1983; 40:539.</a></li><li><a class="nounderline abstract_t">Caciotti A, Morrone A, Domenici R, et al. Severe prognosis in a large family with hypokalemic periodic paralysis. Muscle Nerve 2003; 27:165.</a></li><li><a class="nounderline abstract_t">Layzer RB. Periodic paralysis and the sodium-potassium pump. Ann Neurol 1982; 11:547.</a></li><li><a class="nounderline abstract_t">Resnick JS, Engel WK, Griggs RC, Stam AC. Acetazolamide prophylaxis in hypokalemic periodic paralysis. N Engl J Med 1968; 278:582.</a></li><li><a class="nounderline abstract_t">Links TP, Arnoldus EP, Wintzen AR, et al. The calcium channel blocker verapamil in hypokalemic periodic paralysis. Muscle Nerve 1998; 21:1564.</a></li><li><a class="nounderline abstract_t">Matthews E, Portaro S, Ke Q, et al. Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype. Neurology 2011; 77:1960.</a></li><li><a class="nounderline abstract_t">Tawil R, McDermott MP, Brown R Jr, et al. Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol 2000; 47:46.</a></li><li><a class="nounderline abstract_t">Sansone V, Meola G, Links TP, et al. Treatment for periodic paralysis. Cochrane Database Syst Rev 2008; :CD005045.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/011366Orig1s030ltr.pdf (Accessed on August 11, 2015).</li><li><a class="nounderline abstract_t">Fiore DM, Strober JB. Treatment of hypokalemic periodic paralysis with topiramate. Muscle Nerve 2011; 43:127.</a></li><li><a class="nounderline abstract_t">Tricarico D, Barbieri M, Camerino DC. Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis. Ann Neurol 2000; 48:304.</a></li><li><a class="nounderline abstract_t">Tricarico D, Barbieri M, Mele A, et al. Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats. FASEB J 2004; 18:760.</a></li><li><a class="nounderline abstract_t">Ligtenberg JJ, Van Haeften TW, Van Der Kolk LE, et al. Normal insulin release during sustained hyperglycaemia in hypokalaemic periodic paralysis: role of the potassium channel opener pinacidil in impaired muscle strength. Clin Sci (Lond) 1996; 91:583.</a></li><li><a class="nounderline abstract_t">Kim JB, Lee KY, Hur JK. A Korean family of hypokalemic periodic paralysis with mutation in a voltage-gated calcium channel (R1239G). J Korean Med Sci 2005; 20:162.</a></li><li><a class="nounderline abstract_t">Torres CF, Griggs RC, Moxley RT, Bender AN. Hypokalemic periodic paralysis exacerbated by acetazolamide. Neurology 1981; 31:1423.</a></li><li><a class="nounderline abstract_t">Bendahhou S, Cummins TR, Griggs RC, et al. Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis. Ann Neurol 2001; 50:417.</a></li><li><a class="nounderline abstract_t">Tristani-Firouzi M, Jensen JL, Donaldson MR, et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 2002; 110:381.</a></li><li><a class="nounderline abstract_t">Sansone V, Griggs RC, Meola G, et al. Andersen's syndrome: a distinct periodic paralysis. Ann Neurol 1997; 42:305.</a></li><li><a class="nounderline abstract_t">Kostera-Pruszczyk A, Potulska-Chromik A, Pruszczyk P, et al. Andersen-Tawil syndrome: report of 3 novel mutations and high risk of symptomatic cardiac involvement. Muscle Nerve 2015; 51:192.</a></li><li><a class="nounderline abstract_t">Statland JM, Fontaine B, Hanna MG, et al. Review of the Diagnosis and Treatment of Periodic Paralysis. Muscle Nerve 2018; 57:522.</a></li><li><a class="nounderline abstract_t">Tawil R, Ptacek LJ, Pavlakis SG, et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol 1994; 35:326.</a></li><li><a class="nounderline abstract_t">Davies NP, Imbrici P, Fialho D, et al. Andersen-Tawil syndrome: new potassium channel mutations and possible phenotypic variation. Neurology 2005; 65:1083.</a></li><li><a class="nounderline abstract_t">Kokunai Y, Nakata T, Furuta M, et al. A Kir3.4 mutation causes Andersen-Tawil syndrome by an inhibitory effect on Kir2.1. Neurology 2014; 82:1058.</a></li></ol></div><div id="topicVersionRevision">Topic 5150 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19185183" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8770943" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Periodic paralysis and voltage-gated ion channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1635436" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1660744" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8758050" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Thyrotoxic periodic paralysis in a Chinese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15667036" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Thyrotoxic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16608889" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7847370" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23019082" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Gender differences in penetrance and phenotype in hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15534250" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Correlating phenotype and genotype in the periodic paralyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16195244" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The primary periodic paralyses: diagnosis, pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8004673" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dihydropyridine receptor mutations cause hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9066893" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Identification of mutations in the CACNL1A3 gene in 13 families of Scandinavian origin having hypokalemic periodic paralysis and evidence of a founder effect in Danish families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15726306" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Novel CACNA1S mutation causes autosomal dominant hypokalemic periodic paralysis in a Chinese family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118277" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8605978" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Electrophysiological properties of the hypokalaemic periodic paralysis mutation (R528H) of the skeletal muscle alpha 1s subunit as expressed in mouse L cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9852570" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gating of the L-type Ca channel in human skeletal myotubes: an activation defect caused by the hypokalemic periodic paralysis mutation R528H.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2903448" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Restoration of excitation-contraction coupling and slow calcium current in dysgenic muscle by dihydropyridine receptor complementary DNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10074484" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Impairment of skeletal muscle adenosine triphosphate-sensitive K+ channels in patients with hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534267" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K+ current.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11353725" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10599760" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A novel sodium channel mutation in a family with hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21490317" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Leaky sodium channels from voltage sensor mutations in periodic paralysis, but not paramyotonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17330043" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Gating pore current in an inherited ion channelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29769724" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Structural basis for gating pore current in periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24549961" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : NaV1.4 mutations cause hypokalaemic periodic paralysis by disrupting IIIS4 movement during recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23988599" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acute hypokalemic periodic paralysis possibly precipitated by albuterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2276049" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Permanent muscle weakness in familial hypokalaemic periodic paralysis. Clinical, radiological and pathological aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1381862" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Muscle pathology correlates with permanent weakness in hypokalemic periodic paralysis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32580975" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Permanent muscle weakness in hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32954434" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Vacuoles, Often Containing Glycogen, Are a Consistent Finding in Hypokalemic Periodic Paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5433278" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Acetazolamide treatment of hypokalemic periodic paralysis. Prevention of attacks and improvement of persistent weakness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6855804" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8195801" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Familial hypokalemic periodic paralysis. Clinical, diagnostic and therapeutic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15351880" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A hidden cause of hypokalemic paralysis in a patient with prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11642520" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Primary Sjögren's syndrome presenting as hypokalaemic periodic paralysis and respiratory arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7575850" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Renal tubular acidosis complicated with hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7860528" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hypokalaemic periodic paralysis associated with thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10715756" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hypokalaemic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277290" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Laboratory tests to determine the cause of hypokalemia and paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25447623" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Etiologic and therapeutic analysis in patients with hypokalemic nonperiodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29667944" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Proximal Muscle Weakness With Overlying Hypokalemic Periodic Paralysis in Sjögren Syndrome: Report of 6 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11259688" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hypokalaemia and paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15510933" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Severe hypophosphatemia in a patient with diabetic ketoacidosis and acute respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17000984" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hypokalemic paralysis due to Gitelman syndrome: a family study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187194" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hypokalaemia and paralysis in the Thai population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187194" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hypokalaemia and paralysis in the Thai population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8385612" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Use of corticotropin-induced potassium changes in the diagnosis of both hypo- and hyperkalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24753672" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Reversible electrophysiological abnormalities in hypokalemic paralysis: Case report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557559" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cold induces shifts of voltage dependence in mutant SCN4A, causing hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29752813" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Long Exercise Test in Periodic Paralysis: A Bayesian Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34817893" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The long exercise test as a functional marker of periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3785281" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The exercise test in periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14966175" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The exercise test as a monitor of disease status in hypokalaemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10883004" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Exercise test in muscle channelopathies and other muscle disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389891" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Electromyography guides toward subgroups of mutations in muscle channelopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389891" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Electromyography guides toward subgroups of mutations in muscle channelopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10090117" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14980336" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The pitfalls of potassium replacement in thyrotoxic periodic paralysis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15666258" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15678291" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Thyrotoxic periodic paralysis complicated by near-fatal ventricular arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6412669" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Intravenous treatment of hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12548523" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Severe prognosis in a large family with hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6287910" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Periodic paralysis and the sodium-potassium pump.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5637755" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Acetazolamide prophylaxis in hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9771691" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The calcium channel blocker verapamil in hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22094484" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10632100" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18254068" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Treatment for periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18254068" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment for periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21171065" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of hypokalemic periodic paralysis with topiramate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10976636" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14766795" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8942397" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Normal insulin release during sustained hyperglycaemia in hypokalaemic periodic paralysis: role of the potassium channel opener pinacidil in impaired muscle strength.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15716625" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A Korean family of hypokalemic periodic paralysis with mutation in a voltage-gated calcium channel (R1239G).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7031501" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Hypokalemic periodic paralysis exacerbated by acetazolamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11558801" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12163457" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9307251" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Andersen's syndrome: a distinct periodic paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24861851" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Andersen-Tawil syndrome: report of 3 novel mutations and high risk of symptomatic cardiac involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29125635" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Review of the Diagnosis and Treatment of Periodic Paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8080508" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16217063" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Andersen-Tawil syndrome: new potassium channel mutations and possible phenotypic variation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24574546" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A Kir3.4 mutation causes Andersen-Tawil syndrome by an inhibitory effect on Kir2.1.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
